Congresswoman Schakowsky Announces Inclusion of Her Lymphedema Treatment Act In H.R. 3
WASHINGTON, DC – Today, Congresswoman Jan Schakowsky (IL-09), a Senior Chief Deputy Whip and Chair of the Energy and Commerce Consumer Protection and Commerce Subcommittee, announced that her Lymphedema Treatment Act (H.R. 1948) will be included in the version of H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act of 2019, that will be voted on in the House next week. Her bipartisan and bicameral legislation was introduced alongside Representatives Buddy Carter (R-GA), Earl Blumenauer (D-OR), and Mike Kelly (R-PA) in March 2019 with 93 original cosponsors; today, H.R. 1948 has 365 cosponsors, making it the most widely supported health care bill in the 116th Congress. The Lymphedema Treatment Act would ensure Medicare Part B coverage of compression therapy, the clinically-recognized treatment for lymphedema.
"I have seen Lymphedema in a close friend of mine, so I know that it can be a painful and costly condition to treat and manage on top of struggling with cancer," said Congresswoman Schakowsky."I want to thank Speaker Nancy Pelosi, Chairman Frank Pallone Jr., Chairman Richard E. Neal, and Chairman Bobby Scott for including my legislation in H.R. 3. In addition to transforming our prescription drug market, the Elijah E. Cummings Lower Drug Costs Now Act will now make sure that those dealing with lymphedema don't also have to worry about the cost of treating it. Nearly all of my colleagues in the House have cosponsored the Lymphedema Treatment Act and I look forward to finally passing this critical legislation next week."
Lymphedema is a chronic, progressive group of conditions characterized by swelling and discomfort in various parts of the body due to malfunctions in the lymphatic system. Between 1.5 and 3 million Medicare beneficiaries currently suffer from lymphedema. Patients undergoing treatment for cancer are particularly susceptible to lymphedema. When left untreated or undertreated, lymphedema can lead to complications, infections, comorbidities, loss of function, and disability—often necessitating costly emergency department or hospital visits. Commercial insurance and state Medicaid programs currently cover compression therapy.
The Lymphedema Treatment Act enjoys strong support from a broad coalition of patient advocacy, provider, and industry groups, including the Lymphedema Advocacy Group; the American Cancer Society; the American Medical Association; the Lymphatic Education and Research Network; 3M; the Oncology Nursing Society; the American Physical Therapy Association; the American Occupational Therapy Association; American Academy of Physical Medicine & Rehabilitation; American Association of Nurse Practitioners; American Lymphedema Framework Project; American Nurses Association; Breast Cancer Action; Cancer Legal Care; Disability Rights Legal Center; Greet The Day; LIVESTRONG; Lighthouse Lymphedema Network; Living Beyond Breast Cancer; Lipedema Foundation; Lymphology Association of North America; National Comprehensive Cancer Network; National Lymphedema Network; National Patient Advocate Foundation; Northwest Lymphedema Center; Ovarian Cancer National Alliance; Society for Gynecologic Oncology; Society for Vascular Nursing; Susan G. Komen; Wound, Ostomy and Continence Nurses Society; Ackerman Cancer Center; Dana-Farber Cancer Institute; Boston Children's Hospital, Vascular Anomalies Center; Essentially Women, a division of VGM Group, Inc.; EveryLife Foundation for Rare Diseases; James Cancer Hospital & Solove Research Institute at The Ohio State University; Moffitt Cancer Center; Penn Medicine Cancer Rehabilitation; Phelan McDermid Syndrome Foundation; Seattle Cancer Care Alliance; UNC Lineberger Comprehensive Cancer Center; University of Vermont Cancer Center
###